Cargando…

Small Molecule Bax Agonists for Cancer Therapy

Bax, a central death regulator, is required at the decisional stage of apoptosis. We recently identified serine 184 (S184) of Bax as a critical functional switch controlling its proapoptotic activity. Here, we employed the structural pocket around S184 as a docking site to screen the NCI library of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xin, Meiguo, Li, Rui, Xie, Maohua, Park, Dongkyoo, Owonikoko, Taofeek K., Sica, Gabriel L., Corsino, Patrick E., Zhou, Jia, Ding, Chunyong, White, Mark A., Magis, Andrew T., Ramalingam, Suresh S., Curran, Walter J., Khuri, Fadlo R., Deng, Xingming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4172359/ https://www.ncbi.nlm.nih.gov/pubmed/25230299 http://dx.doi.org/10.1038/ncomms5935

Ejemplares similares

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

Discovery of Small Molecule Bak Activator for Lung Cancer Therapy
por: Park, Dongkyoo, et al.
Publicado: (2021)

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2020)

Mono- or Double-Site Phosphorylation Distinctly Regulates the Proapoptotic Function of Bax
por: Wang, Qinhong, et al.
Publicado: (2010)

GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth
por: Koo, Junghui, et al.
Publicado: (2015)

GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth
por: Koo, Junghui, et al.
Publicado: (2021)

Bcl2 inhibits recruitment of Mre11 complex to DNA double-strand breaks in response to high-linear energy transfer radiation
por: Xie, Maohua, et al.
Publicado: (2015)

The Combination of RAD001 and NVP-BEZ235 Exerts Synergistic Anticancer Activity against Non-Small Cell Lung Cancer In Vitro and In Vivo
por: Xu, Cheng-Xiong, et al.
Publicado: (2011)

Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study
por: Pakkala, Suchita, et al.
Publicado: (2020)

Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer
por: Owonikoko, Taofeek K., et al.
Publicado: (2016)

Statistical learning methods as a preprocessing step for survival analysis: evaluation of concept using lung cancer data
por: Behera, Madhusmita, et al.
Publicado: (2011)

Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing
por: Oh, You-Take, et al.
Publicado: (2015)

Interactive Software “Isotonic Design using Normalized Equivalent Toxicity Score (ID-NETS©TM)” for Cancer Phase I Clinical Trials
por: Chen, Zhengjia, et al.
Publicado: (2013)

Inhibition of STAT3 by Niclosamide Synergizes with Erlotinib against Head and Neck Cancer
por: Li, Rui, et al.
Publicado: (2013)

Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer
por: Owonikoko, Taofeek K, et al.
Publicado: (2014)

Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models
por: Owonikoko, Taofeek K., et al.
Publicado: (2019)

A Bystander Effect of Lung Cancer Chemotherapy on Chronic Echinococcal Disease
por: Bangaru, Saroja D., et al.
Publicado: (2015)

Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
por: Zang, Hongjing, et al.
Publicado: (2020)

Targeting DNA Replication Stress for Cancer Therapy
por: Zhang, Jun, et al.
Publicado: (2016)

Combination of heat shock protein 90 and focal adhesion kinase inhibitors synergistically inhibits the growth of non-small cell lung cancer cells
por: Webber, Philip J., et al.
Publicado: (2015)

In Lebanon “It Never Rains But It Pours”—How the American University of Beirut faced dangers and seized opportunities: Transforming medical education through multiple crises
por: Khuri, Fadlo R.
Publicado: (2021)

The E3 ubiquitin ligases β-TrCP and FBXW7 cooperatively mediates GSK3-dependent Mcl-1 degradation induced by the Akt inhibitor API-1, resulting in apoptosis
por: Ren, Hui, et al.
Publicado: (2013)

Small Molecule Allosteric Inhibitors of BAX
por: Garner, Thomas P., et al.
Publicado: (2019)

Adaptive Estimation of Personalized Maximum Tolerated Dose in Cancer Phase I Clinical Trials Based on All Toxicities and Individual Genomic Profile
por: Chen, Zhengjia, et al.
Publicado: (2017)

Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma
por: Harvey, R. Donald, et al.
Publicado: (2020)

Management and Outcomes of Hospitalized Patients With Primary Neuroendocrine Tumor and Non-Neuroendocrine Tumor Appendiceal Cancers in the United States
por: Alese, Olatunji B., et al.
Publicado: (2015)

Downregulation of death receptor 4 is tightly associated with positive response of EGFR mutant lung cancer to EGFR-targeted therapy and improved prognosis
por: Zhang, Shuo, et al.
Publicado: (2021)

Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy
por: Nazha, Bassel, et al.
Publicado: (2020)

Small molecules reveal an alternative mechanism of Bax activation
por: Brahmbhatt, Hetal, et al.
Publicado: (2016)

Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer
por: Brodie, Seth A., et al.
Publicado: (2015)

A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer
por: Bauman, Julie E., et al.
Publicado: (2022)

A Homogenous Luminescent Proximity Assay for 14-3-3 Interactions with Both Phosphorylated and Nonphosphorylated Client Peptides
por: Du, Yuhong, et al.
Publicado: (2008)

BAX as the mediator of C-MYC sensitizes acute lymphoblastic leukemia to TLR9 agonists
por: Bai, Ling, et al.
Publicado: (2023)

Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion
por: Das, Millie, et al.
Publicado: (2021)

Pro-apoptotic Bax molecules densely populate the edges of membrane pores
por: Kuwana, Tomomi, et al.
Publicado: (2016)

Expression of tdTomato and luciferase in a murine lung cancer alters the growth and immune microenvironment of the tumor
por: Huang, Lei, et al.
Publicado: (2021)

EZH2 has a Non-Catalytic and PRC2-Independent Role in Stabilizing DDB2 to Promote Nucleotide Excision Repair
por: Koyen, Allyson E., et al.
Publicado: (2020)

Bcl2 inhibition of mitochondrial DNA repair
por: Xie, Maohua, et al.
Publicado: (2015)

Concurrent Androgen Deprivation Therapy for Prostate Cancer Improves Survival for Synchronous or Metachronous Non-Small Cell Lung Cancer: A SEER–Medicare Database Analysis
por: Nazha, Bassel, et al.
Publicado: (2022)

The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition
por: Yao, Weilong, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_erd7nrd8h2stebe2497rij2c5p